인쇄하기
취소

Patients with kidney cancer to pay only 10% of Nexava NHI price.

Published: 2007-03-30 06:58:00
Updated: 2007-03-30 06:58:00
The NHI reimbursement of Nexava, a new oral anti-kidney cancer drug (sorafenib) and first in its kind in the world, has been approved by the MOHW. Now, the patient may pay only 10% of the drug charges under the NHI coverage. The NHI price for Nexava 200mg tablet is 25,486 won/T taking effects from April 1 this year.
Nexava was first approved by the U. S. FDA in Dec. 2005 for the treatment of k...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.